VRTX - Company ID 0000875320
The table below shows VERTEX PHARMACEUTICALS INC / MA's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.44B | $3.33B | $2.99B | $3.08B | $2.96B | $2.77B |
| Cost of revenue | $526.10M | $489.20M | $392.80M | $414.80M | $407.50M | $363.00M |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
VERTEX PHARMACEUTICALS INC / MA reported annual revenue of $12.00B for fiscal year 2025. That is up 8.9% from $11.02B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $1.70B (FY 2016) to $12.00B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $844.10M |
| $582.20M |
| $493.70M |
| $445.10M |
| $424.60M |
| $396.40M |
| Operating income | $712.90M | $1.25B | $1.14B | $1.19B | $1.15B | $630.10M |
| Income tax | $129.80M | $292.00M | $221.50M | $215.90M | $250.10M | $84.10M |
| Net income | $653.60M | $1.10B | $1.03B | $1.08B | $1.03B | $646.30M |
| EPS (diluted) | $2.56 | $4.31 | $4.02 | $4.20 | $3.99 | $2.49 |